Loading...

Smith & Nephew plc

SNNNYSE
Healthcare
Medical - Devices
$37.49
$0.52(1.41%)

Smith & Nephew plc (SNN) Financial Performance & Income Statement Overview

Explore the financials of Smith & Nephew plc (SNN), including yearly and quarterly data on income, cash flow, and balance sheets.

Revenue Growth
4.70%
4.70%
Operating Income Growth
54.59%
54.59%
Net Income Growth
56.65%
56.65%
Operating Cash Flow Growth
62.34%
62.34%
Operating Margin
12.79%
12.79%
Gross Margin
70.04%
70.04%
Net Profit Margin
8.27%
8.27%
ROE
9.14%
9.14%
ROIC
8.35%
8.35%

Smith & Nephew plc (SNN) Income Statement & Financial Overview

View the income breakdown for Smith & Nephew plc SNN across both annual and quarterly reports.

MetricQ2 2024Q1 2024Q4 2023Q2 2023
Revenue$1.41B$1.41B$2.79B$2.73B
Cost of Revenue$426.50M$426.50M$886.90M$836.00M
Gross Profit$987.00M$987.00M$1.91B$1.90B
Gross Profit Ratio$0.70$0.70$0.68$0.69
R&D Expenses$68.50M$68.50M$171.63M$166.00M
SG&A Expenses$754.50M$754.50M$1.29B$1.42B
Operating Expenses$823.00M$830.00M$1.46B$1.58B
Total Costs & Expenses$1.25B$1.26B$2.35B$2.42B
Interest Income$0.00$30.50M$15.87M$18.00M
Interest Expense$0.00$0.00$76.39M$62.00M
Depreciation & Amortization$96.00M$96.00M$382.93M$297.00M
EBITDA$260.00M$260.00M$547.61M$590.00M
EBITDA Ratio$0.18$0.18$0.30$0.22
Operating Income$164.00M$164.00M$444.44M$315.00M
Operating Income Ratio$0.12$0.12$0.16$0.12
Other Income/Expenses (Net)-$37.50M-$37.50M-$356.15M-$44.00M
Income Before Tax$126.50M$126.50M$88.29M$231.00M
Income Before Tax Ratio$0.09$0.09$0.03$0.08
Income Tax Expense$19.50M$19.50M-$11.90M$39.00M
Net Income$107.00M$107.00M$90.28M$172.00M
Net Income Ratio$0.08$0.08$0.03$0.06
EPS$0.12$0.12$0.21$0.40
Diluted EPS$0.12$0.12$0.21$0.40
Weighted Avg Shares Outstanding$873.47M$873.47M$435.94M$435.07M
Weighted Avg Shares Outstanding (Diluted)$873.47M$873.47M$439.22M$435.07M

Over the last four quarters, Smith & Nephew plc achieved steady financial progress, growing revenue from $2.73B in Q2 2023 to $1.41B in Q2 2024. Gross profit stayed firm with margins at 70% in Q2 2024 versus 69% in Q2 2023. Operating income totaled $164.00M in Q2 2024, maintaining a 12% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at $260.00M. Net income rose to $107.00M, with EPS at $0.12. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;